A revised international staging system (R-ISS) from the IMWG provides the most up-to-date tool for stratifying patient risk based on prognosis.
The Durie-Salmon Staging System is another staging system that correlates the amount of myeloma to the damage it has caused, such as bone disease or anemia.
Careful testing after each cycle of treatment will indicate whether the treatment is working or not. If response is slow and side-effects are manageable, additional therapy should be considered. Thus, accurate response assessment is important. As shown below, there is a correlation between test results and the number of myeloma cells.
IMWG response criteria - if the response is less than desired, the practitioner and patient should discuss whether to watch and wait, switch therapies, or continue with a maintenance dose.
The Advanced Practitioner's Guide to Multiple Myeloma
JADPRO Vol. 7 | Supplement 1 | March 2016
Updates in the Diagnosis and Monitoring of Multiple Myeloma
Comprised of oncology-certified nurses, the Nurse Leadership Board has extensive knowledge of the multiple myeloma treatment and care landscape. These resources were developed by their team.
Last Medical Review: August 1, 2019